Picture of Axsome Therapeutics logo

AXSM Axsome Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m-4.53%
3m-4.21%
6m-9.04%
1yr-1.32%
Volume Change (%)
10d/3m+24.17%
Price vs... (%)
52w High-18.03%
50d MA-4.45%
200d MA+6.87%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value20.01
Price to Tang. Book30.41
Price to Free Cashflown/a
Price to Sales14.12
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-51.59%
Return on Equity-159.21%
Operating Margin-85.67%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Axsome Therapeutics EPS forecast chart

Profile Summary

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
January 12th, 2012
Public Since
November 19th, 2015
No. of Shareholders
2
No. of Employees
545
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
47,374,375

AXSM Share Price Performance

Upcoming Events for AXSM

Q1 2024 Axsome Therapeutics Inc Earnings Release

Axsome Therapeutics Inc Annual Shareholders Meeting

Q2 2024 Axsome Therapeutics Inc Earnings Release

Similar to AXSM

Picture of 111 logo

111

us flag iconNASDAQ Global Market

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

FAQ